Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Newton: Niraparib RADAR Dosing in Recurrent Ovarian Cancer
NCT03891576Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (3 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Occurrence of grade >=3 thrombocytopenia at 3 months. Started Nov 2019; status: terminated.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03891576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891576.